Chardan Capital Maintains Buy on Metagenomi, Lowers Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Geulah Livshits maintains a Buy rating on Metagenomi (NASDAQ:MGX) but lowers the price target from $17 to $15.
August 19, 2024 | 12:35 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Chardan Capital's analyst Geulah Livshits continues to recommend buying Metagenomi stock but has reduced the price target from $17 to $15, indicating a slightly less optimistic outlook.
The maintained Buy rating suggests continued confidence in Metagenomi's potential, but the lowered price target reflects a tempered outlook, possibly due to market conditions or company performance. This mixed signal may result in neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100